Browse Related Topics For:

Hatch-Waxman

115
Patents
107
Pharmaceutical Industry
99
Generic Drugs
83
Pharmaceutical Patents
76
Patent Infringement
71
Patent Litigation
62
ANDA
55
Prescription Drugs
52
FDA
32
SCOTUS
30
FTC
26
FTC v Actavis
26
Reverse Payment Settlement Agreements
14
BPCIA
14
Pay-For-Delay
12
Antitrust Litigation
12
Biosimilars
12
Inter Partes Review Proceedings
12
Teva Pharmaceuticals
10
Anti-Competitive
10
Sandoz
10
Settlement
9
Actavis Inc.
9
Mylan Pharmaceuticals
9
Personal Jurisdiction
9
Safe Harbors
8
AstraZeneca
8
Patent Trial and Appeal Board
7
America Invents Act
7
Biologics
7
Cephalon
7
Popular
6
Appeals
6
DaimlerChrysler v Bauman
6
Declaratory Judgments
6
FDCA
6
Prior Art
6
USPTO
5
Apotex
5
Claim Construction
5
Classen Immunotherapies
5
Eli Lilly
5
GlaxoSmithKline
5
Infringement
5
Obviousness
5
Otsuka Pharmaceutical
5
Patent Applications
5
Patent Reform
5
Preliminary Injunctions
5
Rule-of-Reason Analysis
5
Sandoz v Amgen
5
Sherman Act
5
Teva v Sandoz
5
Watson Pharmaceuticals
4
Amgen
4
FDA Approval
4
Merck
4
Novartis
4
Orange Book
4
Patent-in-Suit
4
Reverse Payments
4
Standard of Review
3
Biologics Price Competition and Innovation Act of 2009
3
Biotechnology
3
Class Action
3
Corporate Counsel
3
De Novo Standard of Review
3
Elan Pharmaceuticals
3
Healthcare
3
Hedge Funds
3
Innovation Act
3
Jurisdiction
3
Patent Dance
3
Patent Invalidity
3
Patent Trolls
3
Preemption
3
Putative Class Actions
3
Specific Jurisdiction
3
Standing
3
Summary Judgment
3
Takeda Pharmaceuticals
3
Unfair Competition
2
Allergan Inc
2
Antitrust Provisions
2
Biogen Idec
2
Burden of Proof
2
CA Supreme Court
2
Cartwright Act
2
Commercial Marketing
2
DaimlerAG
2
Damages
2
Disclosure Requirements
2
Disgorgement
2
Dismissals
2
Doctrine of Equivalents
2
Endo Pharmaceuticals
2
Exclusivity
2
Failure To Warn
2
Federal Rule 12(b)(6)
2
Generic
2
Hospira
2
Induced Infringement
2
Injunctions
2
Innovation
2
Intellectual Property Litigation
2
Labeling
2
Life Sciences
2
Manufacturers
2
Medicare Modernization Act
2
Minimum Contacts
2
Monopolization
2
Motion to Dismiss
2
Motion To Stay
2
No-AG Agreement
2
Non-Practicing Entities
2
Noninfringement
2
Patent-Eligible Subject Matter
2
Pleading Standards
2
Presumption of Validity
2
Product Hopping
2
Spectrum
2
Subject Matter Jurisdiction
2
Validity
1
aBLA
1
Abuse of Process
1
Affordable Care Act
1
Allergan v Sandoz
1
Amarin
1
AMP v Myriad
1
Annual Reports
1
Antibiotics
1
Antitrust Conspiracies
1
Antitrust Injuries
1
Antitrust Violations
1
Article III
1
Attorney Disbarrment
1
Attorney-Client Privilege
1
Balancing Test
1
Bayer
1
Bifurcation
1
Biofuel
1
Biopharmaceutical
1
Bipolar Disorder
1
Boehringer
1
Bowman v Monsanto
1
Brand
1
Broadest Reasonable Interpretation Standard
1
Burden-Shifting
1
But For Causation
1
CAFA
1
Cancer
1
Certiorari
1
Chevron Deference
1
Cipro
1
Cisco v CommilUSA
1
Claim Preclusion
1
Class Certification
1
Clear and Convincing Evidence
1
Clear Error Standard
1
Clinical Trials
1
Coca Cola
1
Collateralized Debt Obligations
1
Combination Products
1
Competition
1
Compliance
1
Congressional Committees
1
Consent Order
1
Consideration
1
Contraceptives
1
Controlled Substances Act
1
Counterclaims
1
Covered Business Method Proceedings
1
Cuozzo Speed Technologies
1
Dart Cherokee Basin Operating Co. v. Owens
1
DEA
1
Death Penalty
1
Design Defects
1
Design Patent
1
Direct Purchasers
1
Dirks v SEC
1
Discovery
1
Discovery Schedule
1
DNA
1
Drug Approvals
1
Drug Compounding
1
Drug Safety
1
Duty to Deal
1
eBay
1
Emerging Markets
1
Enforcement
1
Enforcement Actions
1
Enforcement Statistics
1
EPA
1
European Patent Office
1
Exemptions
1
Expert Testimony
1
Extrinsic Evidence
1
Fair Market Value
1
False Advertising
1
Federal Jurisdiction
1
Federal Rules of Civil Procedure
1
Financial Crisis
1
Foreign Corporations
1
Forum
1
Forum Shopping
1
Fraud
1
Fresenius
1
General Jurisdiction
1
Genzyme
1
Goodyear
1
Healthcare Costs
1
Hindsight Reconstruction
1
Human Genes
1
India
1
Innovator Liability
1
Insider Trading
1
Integra
1
Intellectual Property Protection
1
Inter Partes Reexamination
1
InterDigital Communications v ITC
1
Internal Investigations
1
Inventions
1
Jazz Pharmaceuticals
1
Joinder
1
Justiciable Controversy
1
KBR (formerly Kellogg Brown & Root)
1
Lanham Act
1
Leave to Amend
1
License Agreements
1
Licensing Rules
1
Loss Causation
1
Manufacturing Defects
1
Market Manipulation
1
Marketing
1
Material Misrepresentation
1
Mayo v. Prometheus
1
Medical Devices
1
Medical Research
1
Misrepresentation
1
Monsanto
1
Morgan Stanley
1
Motion for Reconsideration
1
Mutual Pharmaceuticals v Bartlett
1
Myriad
1
New Trial
1
Notice Requirements
1
Off-Label Use
1
Omissions
1
Omnicare v Laborers District Council
1
On-Sale Bar
1
Orphan Drugs
1
Out-of-State Companies
1
OxyContin
1
Par Pharmaceutical
1
Patent Assertion Entities
1
Patent Exhaustion
1
Patent Term Adjustment
1
Patent-Misuse
1
Patentability Search
1
Pending Legislation
1
Permanent Injunctions
1
Personal Benefit
1
Pfizer
1
PHRMA
1
Pleadings
1
PLIVA v Mensing
1
POM Wonderful
1
Post-Grant Review
1
Premarket Approval Applications
1
Price Manipulation
1
Prilosec
1
Prioritized Examination
1
Privilege Waivers
1
Proctor & Gamble
1
Product Exclusivity
1
Product Labels
1
Professional Conferences
1
Prometheus
1
Proposed Amendments
1
Proposed Regulation
1
Quality Control Plan
1
RanBaxy
1
Registration Requirement
1
Regulatory Agenda
1
Reissue Patents
1
Removal
1
Research and Development
1
Restraining Orders
1
Restraint of Trade
1
Reversal
1
RICO
1
Ripeness
1
ROI
1
Roxane Laboratories
1
Royalties
1
Rulemaking Process
1
Sales Contracts
1
Scienter
1
Settlements
1
Sham Litigation Exception
1
Shire Development v Watson
1
Single Occurrence
1
SmithKline Beecham
1
SNDAs
1
Standard of Proof
1
State Law Tort Claims
1
STRONG Patents Act
1
Supplemental Examination
1
Supply Chain
1
TRIPS Agreement
1
TRO
1
USDA
1
Vacated
1
Vaccinations
1
Valuation
1
Veterinarians
1
Veterinary Products
1
Warner Chilcott
1
White Collar Crimes
1
WIPO
1
Work Product Privilege
1
World Intellectual Property Organisation
1
Written Descriptions